gradientech

Interim report

January-March 2026

Company development

Gradientech AB *SEK thousand*	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales	626	943	5,889
Profit for the period	-21,713	-18,950	-72,284
Cash flow from operating activities	-17,229	-19,916	-72,445
Cash and cash equivalents at end of the period	1,712	35,571	6,965
Equity at the Balance sheet date	49,434	47,905	22,699

First quarter 2026

- Net sales amounted to SEK 626 thousand (943). Please note that quarterly sales may vary as Gradientech's sales to distributors vary throughout the year.
- Net profit/loss amounted to SEK -21,713 thousand (-18,950).
- Earnings per share before and after dilution were SEK -0.67 (-0.63).
- Cash flow from operating activities amounted to SEK -17,229 thousand (-19,916).
- Cash and cash equivalents amounted to SEK 1,712 thousand (35,571) as of March 31, 2026.
- Equity amounted to SEK 49,434 thousand (47,905) as of March 31, 2026.
- In January Gradientech´s distributor Iberlab won a direct tender for QuickMIC® in Portugal for the Hospital Unidade Local de Saúde da Guarda (ULS Guarda). This award underscores the growing clinical adoption of QuickMIC® for routine use and further strengthens Gradientech's commercial footprint in Southern Europe.
- Gradientech entered in February into an exclusive distribution agreement with ELTA 90 MGR for the commercialisation of QuickMIC® in Greece. The agreement marks another important step in Gradientech's European expansion strategy and strengthens the company's presence in Southern Europe.
- In February Gradientech announced a long-term agreement with ELBLAB GmbH in Germany for the use of its QuickMIC® system.
- Gradientech did in February receive feedback from the U.S. Food and Drug Administration (FDA) regarding the company's submitted 510(k) premarket notification for its QuickMIC® system for ultra-rapid anti microbial susceptibility testing (AST) of bacterial isolates. Following an initial period of interactive review, the FDA has requested additional information, primarily related to cybersecurity aspects of the system, as well as limited additional performance testing.
- At the end of March Gradientech announced the outcome of the new issue of shares with preferential rights for existing shareholders resolved by the Board of Directors on February 26, 2026. The Rights issue subscribed to approximately 87 percent and brought Gradientech with approximately SEK 49.2 million before deductions for issue costs, of which SEK 14 million will be used to offset loans, see further below in section "Significant events after the end of the period".

Significant events after the end of the period

- In April, registrations were made on two occasions with the Swedish Companies Registration Office regarding the rights issue decided by the Board of Directors on 26 February 2026. After both registrations, which cash flow affects the second quarter of 2026, the share capital amounts to SEK 3,795,035.90 and the number of shares to 37,950,359.
- In mid-April, the company announced promising preliminary results from its ongoing performance study evaluating a second gram-negative panel for the company's QuickMIC system. The study includes antibiotics that are used as a last-resort treatment option for multidrug-resistant bacteria in sepsis patients, including cefiderocol.
- In April, the company announced that it has been granted patent rights in the US for its single-use test, which is a key component of the CE-marked QuickMIC system.
- In early May, the company announced the publication of a comprehensive European multicenter study showing that the company's QuickMIC system delivers fast and reliable results for antibiotic susceptibility testing (AST) within the same work shift – up to 45 hours faster than conventional methods.
- During April, the Gradientech board of directors and CEO Sara Thorslund jointly agreed that the company needs new leadership to transform Gradientech towards a commercial focus. The recruitment process is ongoing, and a new CEO is expected to take office in the second quarter of 2026. During the transition period, the company's CFO, Urban Adolfsson, will take office as interim CEO.

Gradientech in brief

About Gradientech

Gradientech is a Swedish in vitro diagnostic company that develops, manufactures and sells next-generation solutions for infectious diseases. Our market-approved QuickMIC® system positions us as a world leader in ultra-rapid antibiotic susceptibility testing (AST), enabling sepsis patients with bloodstream infections to receive personalised treatment with the right antibiotic at the right dose – in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance, one of the greatest global health threats of our time.

About QuickMIC®

QuickMIC® diagnoses which antibiotic a patient with bacteria in the blood should be treated with, as well as which antibiotics the bacteria are resistant to. By providing quantitative resistance values in just 2-4 hours, QuickMIC® is currently the fastest AST system on the market, offering direct sampling from blood culture. Its patent-protected technology ensures unique measurement precision, which, combined with the rapid test times, creates the ideal conditions for precision diagnostics and rapid, individualised antibiotic treatment for sepsis patients.

The modular instrument design makes the system scalable, appealing to both small and large hospitals, and offers the potential for sales without the need for procurement processes. QuickMIC® has through its breakthrough device classification benefits from a prioritised review path with the US FDA.

Vision

"Precision medicine – for a sustainable world."

Gradientech's vision is to enable a shift toward precision medicine in infectious disease diagnostics. Through rapid and individualised antibiotic susceptibility testing, our products support earlier, better-informed treatment decisions for sepsis patients. This benefits individual patient outcomes while promoting the rational use of antibiotics, contributing to a more sustainable healthcare system where effective antibiotics remain available for future generations.

Strategic focus

Gradientech's strategic focus is to drive sales of QuickMIC® through a combination of direct sales and distributors across the European market, while continuously increasing the number of instruments in routine clinical use in hospital microbiology laboratories. In parallel, the review of the submitted FDA 510(k) application for the QuickMIC® system is ongoing, with the objective of achieving future FDA clearance and enabling commercialisation of QuickMIC® in the United States together with the company's American commercial partner.

CEO statement

Gradientech started 2026 with continued commercial expansion and several important clinical and strategic advances. During the quarter, the number of contracted European hospitals increased to 20, in line with our targets. Of these, 18 have completed their internal validation enabling the use of QuickMIC® in clinical routine for patient samples. We are also seeing an increase in hospitals in clinical routine, further confirming the growing clinical and commercial impact of our AST solution

The Italian so-called AMCLI study, conducted at four hospitals together with our distributor a.d.a. and the Italian Society of Clinical Microbiology, was recently completed with promising preliminary results. Two of the participating hospitals have already decided to implement QuickMIC® in clinical routine after the study was completed, with one of them choosing to replace previously installed competing fast AST technology to achieve shorter turnaround times. The study is expected to be an important reference point for the definition of clinically effective rapid AST systems in the Italian market.

In the US, the first KOL-study conducted by our distributor Hardy Diagnostics was recently completed at a well-respected hospital. The study shows that QuickMIC® and its US-market adapted antibiotic panel achieve high concordance with established AST and on average over 24 hours faster reporting of results. The study provides further important clinical evidence for continued expansion in the US market.

In April, Gradientech exhibited at the ESCMID Global 2026 trade fair for infectious disease diagnostics in Munich, where a particular interest was directed towards our upcoming second gram-negative panel, which tentatively includes cefiderocol – an important antibiotic for the treatment of multidrug-resistant infections that is currently missing in other automated AST systems.

The development of the QuickMIC® CU as an integrated display solution and improved user experience of the system is progressing, where hardware has been finalised with a planned European market launch in early autumn 2026.

I would like to thank the shareholders for the completed rights issue, which provided the company with approximately SEK 49 million before issue costs and strengthened working capital for continued commercialisation and product development. We are still in a capital-intensive growth phase, where the focus going forward is on increasing the test usage for each installed QuickMIC® instrument used in clinical routine, increasing the number of routine users and securing long-term financing.

We enter the remainder of 2026 with a growing installed base, increasing clinical impact and a product portfolio that continues to differentiate itself through market-leading short turnaround times. The market for rapid susceptibility testing is still in its early stages, and we are confident in the long-term need for ultra-rapid phenotypic AST and the role QuickMIC® can play in the future of infection diagnostics and sepsis care.

Sara Thorslund, CEO Gradientech

Market update

Europe

An increasing number of hospitals in Europe have now implemented QuickMIC® in clinical routine where our customers are primarily located in countries with high antibiotic resistance and thus have a high clinical need for rapid phenotypic AST. We see a gradual transition from the evaluation phase in hospitals, to decisions on clinical implementation and to more frequent use and recurring purchases of tests. This reinforces the picture of a growing clinical acceptance of ultra-rapid AST as part of modern infection diagnostics and sepsis care.

Italy continues to be a strategically important market, where our distributor a.d.a. plays a central role in the clinical expansion. Several hospitals have implemented QuickMIC® in routine use, including cases where the system has replaced previously installed competing rapid AST solutions. The now completed prestige study together with AMCLI, the Italian Society for Clinical Microbiology, contributes important evidence that is expected to support wider national implementation and provide clear evidence of the clinical benefit of rapid AST.

Germany continues to be a focus area for Gradientech's direct sales. Several hospital laboratories have ongoing demo studies and have implemented the QuickMIC® system in their routine operations. Among our routine customers in Germany is also a major diagnostics provider serving a regional hospital network.

Overall, we see a gradually broader European presence with implementation of the QuickMIC® system in several countries in Central and Southern Europe as well as in selected markets in Eastern Europe. The development confirms a clear trend towards increased adoption of rapid phenotypic AST, especially in regions with high levels of antibiotic resistance. The market has high demands for robustness and user-friendly integration into existing workflows, which drives the need for continuous product development and close cooperation with both our distributors and end users.

USA

The US is a strategically important growth market where work is underway to establish QuickMIC® in preparation for a future regulatory FDA clearance. The first US KOL-study with the US-adapted antibiotic panel in the QuickMIC® system has now been completed. The study shows that the QuickMIC® system provides results that show high agreement with established methods and significantly shorter time to AST results. The study strengthens the clinical evidence base and is an important part of the preparations for future market establishment in the US.

QuickMIC® is expected to be the system on the US market with the shortest time to AST results. The US is generally a market with a clear focus on treatment outcomes and where reduced healthcare costs are a strong market driving factor for the implementation of rapid AST.

Financial development in brief

Gradientech AB *SEK thousand (if not stated otherwise)*	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales	626	943	5,889
Operating expenses	-24,708	-21,626	-78,907
Operating result	-21,534	-18,891	-72,542
Profit before tax	-21,713	-18,950	-72,284
Profit for the period	-21,713	-18,950	-72,284
Cash flow from operating activities	-17,229	-19,916	-72,445
Investments in tangible assets	-1,728	-484	-4,643
Cash and cash equivalents at end of the period	1,712	35,571	6,965
Equity at the Balance sheet date	49,434	47,905	22,699
Key ratios			
Return on equity, %	neg	neg	neg
Return on capital employed, %	neg	neg	neg
Earning per share, before dilution, SEK	-0.67	-0.63	-2.28
Earning per share, after dilution, SEK	-0.67	-0.63	-2.28
Equity/asset ratio	82%	87%	75%
Equity per share, SEK	1.53	1.56	0.70
Cash flow from operating activities per share, SEK	-0.53	-0.67	-2.29
Employees at end of period, #	40	37	39

First quarter 2026

Net sales

Net sales for the quarter amounted to SEK 626 thousand (943) and are attributable to sales of QuickMIC® instruments and associated consumables.

Expenses

Expenses during the quarter amounted to SEK 24,708 thousand (21,626) and including Change in inventories to net SEK 22,537 thousand (19,903). Raw materials and purchased services including Change in inventories amounted to net SEK -4,109 thousand (-4,428) and Other external expenses to SEK 7,151 thousand (6,317). Personnel costs amounted to SEK 10,793 thousand (8,681) and number of employees amounted to 40 (37) at the end of the quarter.

Profit for the period

Profit/loss after financial items was SEK -21,713 (-18,950) thousand, or SEK -0.67 (-0.63) per share before and after dilution.

Cash flow, investments and financial position

Cash flow for the quarter amounted to SEK -5,254 thousand (10,975) and cash flow from operating activities amounted to SEK -17,229 thousand (-19,916) or SEK -0.53 (-0.67) per share. Cash flow from operating activities includes changes in working capital of SEK 4,060 thousand (-1,413), including SEK -2,171 thousand (-1,722) from changes in inventories and SEK 2,918 thousand (-1,080) from changes in receivables as well as SEK 3,313 thousand (1,390) from changes in liabilities.

Cash flow from investing activities amounted to SEK -1,728 thousand (-484).

Cash flow from financing activities amounted to SEK 13,702 thousand (31,374) and includes issue costs for the quarter and loans of 14 million SEK, which were converted into shares after the balance sheet date in connection with the Rights Issue, decided by the Board on 26 February 2026. Issue capital received in 2025 relates to the rights issue of shares decided by the Board on 17 December 2024.

Employees

At the end of the period, the number of employees amounted to 40 (37). In addition, at the end of the period, 4 consultants (6) were working full- or part-time for the company.

Share capital

The rights issue, decided by the board on 26 February 2026, was registered at the Swedish Companies Registration Office at two occasions during April 2026, both as events after the balance sheet date. After the registrations, the share capital amounted to a total of SEK 3,795,035.90 and the number of shares to 37,950,359. At the end of the first quarter number of shares amounted to 32,331,232 and the share capital amounted to SEK 3,795,035.90 divided into registered share capital of SEK 3,233,123.20 and unregistered share capital of SEK 561,912.70.

Equity

Equity at the end of the period amounted to SEK 49,434 thousand (47,905) or SEK 1.53 (1.56) per share. The equity/assets ratio at the end of the period was 82 percent (87).

Tax loss carryforward

Gradientech's current operations are initially expected to generate negative earnings and tax losses. There is currently insufficient reason to capitalise the value of the tax loss carryforward, and no deferred tax asset has therefore been recognised. As of December 31, 2025 the total unutilised loss carryforward amounts to to SEK 455,310 thousand (382,206).

Pledged assets

Pledged assets reported in the previous year consist of pledged bank funds of SEK 50 thousand. Gradientech currently has no pledged assets.

Incentive programs

At the AGM on May 7, 2024, the shareholders decided to introduce an employee stock option program of 1,131,125 options that entitle the holders to subscribe for 1,131,125 shares in Gradientech at a price of SEK 17.50 per share upon the achievement of milestones and a vesting period of three years. The dilutive effect is estimated at approximately 4.5 percent on full subscription.

Related party transactions

No transactions between Gradientech and its related parties were carried out during the period.

Financing

The rights issue of shares with preferential rights for existing shareholders decided by the Board on February 26, 2026 was subscribed to approximately 87 percent and provided Gradientech with a total of SEK 49.2 million before deduction for issue costs, of which SEK 14 million is used to offset loans. The issue was registered on two occasions in April as events after the balance sheet date. After both registrations, of which cash flow affects the second quarter of 2026, the share capital amounts to SEK 3,795,035.90 and the number of shares to 37,950,359.

The board of directors' assessment is that the issue proceeds together with existing cash, at the time of submission of this interim report, do not secure financing for at least the next twelve months. In the current market situation, the company's board of directors has chosen to finance the upcoming twelve-month period on more than one occasion. This means that additional issues need to be carried out during the next twelve-month period to ensure the company's continued financing.

Condensed income statement

Gradientech AB *SEK thousand*	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales	626	943	5,889
Change in inventories	2,171	1,722	331
Other operating income	377	69	145
Purchased goods and services	-6,280	-6,150	-16,652
Other external expenses	-7,151	-6,317	-24,001
Personnel costs	-10,793	-8,681	-36,168
Depreciation	-424	-447	-1,884
Other operating expenses	-60	-30	-202
Operating result	**-21,534**	**-18,891**	**-72,542**
Financial net	-179	-59	258
Profit before tax	**-21,713**	**-18,950**	**-72,284**
Income tax	0	0	0
Profit for the period	**-21,713**	**-18,950**	**-72,284**
Average numbers of shares, thousands, before dilution	32,331	29,855	31,680
Average numbers of shares, thousands, after dilution	33,462	30,986	32,811
Number of shares outstanding on the Balance sheet date, thousands	32,331	30,681	32,331
Basic earnings per share, SEK	-0.67	-0.63	-2.28
Diluted earnings per share, SEK	-0.67	-0.63	-2.28

Condensed balance sheet

Gradientech AB	31 Mar		31 Dec
SEK thousand	2026	2025	2025
ASSETS			
Subscribed but unpaid capital	35,167	0	0
Tangible assets			
Equipment, tools, fixtures and fittings	7,903	3,880	6,600
Total non-current assets	**7,903**	**3,880**	**6,600**
Current assets			
Inventories	**4,987**	**4,207**	**2,816**
Current receivables			
Accounts receivables and other receivables	10,855	11,121	13,773
Cash and bank balances	1,712	35,571	6,965
Total current assets	**12,567**	**46,692**	**20,738**
TOTAL ASSETS	**60,624**	**54,779**	**30,154**
EQUITY AND LIABILITIES			
Equity			
Restricted equity	3,795	3,068	3,233
Non-restricted equity	45,639	44,837	19,465
Total equity	**49,434**	**47,905**	**22,699**
Liabilities			
Current liabilities	11,190	6,874	7,455
Total liabilities	**11,190**	**6,874**	**7,455**
TOTAL EQUITY AND LIABILITIES	**60,624**	**54,779**	**30,154**
Pledged assets	**0**	**50**	**0**

Statement of changes in equity

Gradientech AB *SEK thousand*	Share capital	Unregistered share capital	Share premium reserve	Retained earnings	Total
Opening balance, Jan 1, 2025	2,887	0	396,901	-364,364	35,424
Profit/Loss					
Loss for the period				-18,950	-18,950
Total profit/loss	0	0	0	-18,950	-18,950
Transactions with shareholders					
New share issue	181		31,562		31,743
Issue costs			-313		-313
Total transactions with shareholders	181	0	31,249	0	31,431
Closing balance, Mar 31, 2025	**3,068**	**0**	**428,150**	**-383,314**	**47,905**
Opening balance, Jan 1, 2026	3,233	0	456,113	-436,648	22,699
Profit/Loss					
Loss for the period				-21,713	-21,713
Total profit/loss	0	0	0	-21,713	-21,713
Transactions with shareholders					
Ongoing new share issue		562	48,605		49,167
Issue costs			-719		-719
Total transactions with shareholders	0	562	47,886	0	48,448
Closing balance, Mar 31, 2026	**3,233**	**562**	**503,999**	**-458,361**	**49,434**

Condensed cash-flow statement

Gradientech AB *SEK thousand*	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
OPERATING ACTIVITIES			
Result after financial items	-21,713	-18,950	-72,284
Depreciation	424	447	1,884
Cash flow from operating activites before change in working capital	**-21,289**	**-18,503**	**-70,399**
Changes in working capital	4,060	-1,413	-2,046
Cash flow from operating activites	**-17,229**	**-19,916**	**-72,445**
INVESTING ACTIVITIES			
Investments in tangible fixed assets	-1,728	-484	-4,643
Cash flow from investing activites	**-1,728**	**-484**	**-4,643**
Cash flow before financing activities	**-18,956**	**-20,399**	**-77,088**
FINANCING ACTIVITIES			
New share issues, issue costs and loan	13,702	31,374	59,456
Cash flow from financing activites	**13,702**	**31,374**	**59,456**
CASH FLOW FOR THE PERIOD	**-5,254**	**10,975**	**-17,632**
Cash and cash equivalents at beginning of the period	6,965	24,596	24,596
Cash and cash equivalents at end of the period	1,712	35,571	6,965

Accounting principles

This interim report has been prepared in accordance with the Swedish Accounting Standards Board's General Advice and the accounting principles are unchanged compared with the annual report for 2025.

Significant risks and uncertainties

Through its operations, Gradientech is exposed to risks and uncertainties. Information about the company's risks and uncertainties can be found on page 39 in the company's annual report for 2025, which is available on the company's website www.gradientech.se.

Patents and intellectual property rights

Patent

Current patent situation

Gradientech is the owner of four patent families and works with Barker Brettell Sweden AB in Stockholm as patent advisor.

The first patent family relates to the use of the company's microfluidic technology for precise antibiotic susceptibility testing and was filed in July 2014. The patent family includes eight approved patents in Germany, France, UK, Sweden, Japan, China and the US (two approved patents in the US).

The second patent family relates to the design and functions of the microfluidics cassette that constitutes the consumable in the QuickMIC system and was filed in April 2019. The patent family currently includes seven approved patents in Germany, France, the UK, Sweden, Japan, China and the US.

The third patent family concerns a surface modification of plastic surfaces to improve the adhesion of hydrogel to it. A Swedish patent application was filed in April 2022, and was supplemented with an international patent application in March 2023.

The fourth patent family concerns the use of machine learning-based methods to be able to detect antibiotic resistance and resistance mechanisms early during a QuickMIC test run. A Swedish patent application was submitted in August 2023 and was supplemented with an international patent application in March 2024.

IP Strategy

Gradientech develops, manufactures and sells microfluidic products for cell study applications, in infectious disease diagnostics specifically. We regularly review our innovations to determine whether they are patentable and strategically significant for us to seek patent protection. We do this in consultation with our patent office and patent attorney, who have worked with our patent families for a long time. Our strategy is to protect technological solutions and applications in commercially viable markets, mainly in Europe and the US, but also in other selected markets in Asia, for example. The trademark portfolio is managed in partnership with an external legal partner specialised in trademarks.

Trademarks

Gradientech currently has three different brand families.

The first brand family refers to GRADIENTECH® and was filed in January 2010 in trademark classes 1, 5, 9 and 42. The trademark family includes a Swedish registered trademark.

The second brand family refers to CELLDIRECTOR® and was submitted in January 2010 in trademark classes 1, 5 and 9 (as well as class 10 in Sweden). The trademark family includes registered trademarks in Sweden, the USA (only class 1 and 9) and EU trademarks.

The third brand family relates to QUICKMIC® and was submitted in November 2017 in trademark classes 5 and 10. The trademark family includes registered trademarks in the United States and EU trademarks.

Definitions and key ratios

Earnings per share
Net income divided by average number of shares.

Average number of shares
The average number of shares in Gradientech has been calculated based on a weighting of the historical number of outstanding shares in Gradientech after each completed new share issue per its settlement date times the number of days that each number of shares has been outstanding.

Solidity
Equity in relation to balance sheet total (total assets).

Return on equity
Profit after tax in relation to equity.

Return on capital employed
Profit after net financial items in relation to capital employed.

Capital employed
Total assets less non-interest-bearing liabilities.

Equity per share
Equity divided by the number of shares at the balance sheet date.

Cash flow from operating activities per share
Cash flow from operating activities divided by the average number of shares.

Definitions

AST
Antibiotic Susceptibility Testing

Bloodstream infection
Presence of bacteria in the blood

Breakthrough device
Classification by the US FDA of a medical device that is deemed to offer a more effective treatment or diagnosis of life-threatening diseases compared to what is available on the market, provides a prioritised regulatory review process

BSI
The company's Certification Body for the ISO13485 certification and Notified Body for IVDR review

CE
Conformité Européenne, product marking mainly within the European Union and the European Economic Area

CE-IVD
Regulatory marking of diagnostic medical devices that have met a number of requirements, including safety, quality, validity and traceability, that are necessary for the product to be used for diagnostic testing

ESCMID
The European Society of Clinical Microbiology and Infectious Diseases, a European organisation in clinical microbiology and infection diagnostics, organises the annual world conference *ESCMID Global*

FDA
The United States Food and Drug Administration, approves and clears IVD-products for the US market

Gram-negative
The difference between gram-negative and gram-positive bacteria is the structure of their cell walls

Isolate
A single species of a bacterium obtained in a pure culture

IVD
In vitro diagnostics, refers to medical devices for in vitro diagnostics

IVDR
Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices

Microfluidics
The study of how liquids that are physically confined to the micrometer scale in at least one dimension behave, are measured and manipulated

QuickMIC®
Registered trademark of Gradientech, the company's diagnostic system for ultra-rapid antibiotic susceptibility testing

Sepsis
A condition of life-threatening organ dysfunction caused by a disturbed systemic response to infection

Upcoming reports

Annual General Meeting	May 18, 2026
Interim report Q2 2026	August 20, 2026
Interim report Q3 2026	November 12, 2026
Year-end report 2026	February 19, 2027

This interim report has not been reviewed by the company's auditor.

Board of Directors

The Board of Directors and the CEO affirm that interim report provides a true and fair overview of the operations, position and earnings of the company.

Uppsala, May 13, 2026

Gisela Sitbon
Chair of the Board

Henrik Didner
Board member

Rolf Ehrström
Board member

Veronica Byfield Sköld
Board member

Hilja Ibert
Board member

Nedal Safwat
Board member

Sara Thorslund
CEO

For further information, please contact:

Sara Thorslund, CEO
sara.thorslund@gradientech.se

Urban Adolfsson, CFO
urban.adolfsson@gradientech.se

Ann Charlotte Svensson, IR
ir@gradientech.se

gradientech

Uppsala Science Park
SE-751 83 UPPSALA
www.gradientech.se